Our most advanced indication is the treatment of neuropathic pain. We have completed a phase 2a clinical pilot study with results published in 2026. We are preparing a phase 2b clinical study for the treatment of severe peripheral neuropathic pain. 

Due to the activity profile of RM191A, there is the potential to develop further indications in the future.